Astellas Pharma Stock Gross Profit
| ALPMF Stock | USD 9.68 0.07 0.72% |
Astellas Pharma fundamentals help investors to digest information that contributes to Astellas Pharma's financial success or failures. It also enables traders to predict the movement of Astellas Pink Sheet. The fundamental analysis module provides a way to measure Astellas Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Astellas Pharma pink sheet.
Astellas |
Astellas Pharma Company Gross Profit Analysis
Astellas Pharma's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Astellas Pharma Gross Profit | 1.04 T |
Most of Astellas Pharma's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Astellas Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Astellas Pharma reported 1.04 T of gross profit. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The gross profit for all United States stocks is significantly lower than that of the firm.
Astellas Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Astellas Pharma's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Astellas Pharma could also be used in its relative valuation, which is a method of valuing Astellas Pharma by comparing valuation metrics of similar companies.Astellas Pharma is currently under evaluation in gross profit category among its peers.
Astellas Fundamentals
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 26.19 B | |||
| Shares Outstanding | 1.83 B | |||
| Shares Owned By Insiders | 0.37 % | |||
| Shares Owned By Institutions | 50.43 % | |||
| Price To Earning | 25.09 X | |||
| Price To Book | 2.38 X | |||
| Price To Sales | 0.02 X | |||
| Revenue | 1.3 T | |||
| Gross Profit | 1.04 T | |||
| EBITDA | 241.52 B | |||
| Net Income | 124.09 B | |||
| Cash And Equivalents | 336.76 B | |||
| Cash Per Share | 184.77 X | |||
| Total Debt | 4.87 B | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 1.34 X | |||
| Book Value Per Share | 861.58 X | |||
| Cash Flow From Operations | 257.44 B | |||
| Earnings Per Share | 0.57 X | |||
| Target Price | 50.0 | |||
| Number Of Employees | 14.52 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 26.66 B | |||
| Total Asset | 2.33 T | |||
| Retained Earnings | 941.23 B | |||
| Working Capital | 491.17 B | |||
| Current Asset | 874.69 B | |||
| Current Liabilities | 383.53 B | |||
| Z Score | 3.0 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 2.25 % | |||
| Net Asset | 2.33 T | |||
| Last Dividend Paid | 25.0 |
About Astellas Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Astellas Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Astellas Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Astellas Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Astellas Pink Sheet
Astellas Pharma financial ratios help investors to determine whether Astellas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Astellas with respect to the benefits of owning Astellas Pharma security.